References
[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395(10223):497-506.
[2] Lai CC, Yu WL. COVID-19 associated with pulmonary aspergillosis: A literature review. J Microbiol Immunol Infect . 2021;54(1):46-53.
[3] Patti RK, Dalsania NR, Somal N, Sinha A, Mehta S, Ghitan M et al. Subacute Aspergillosis ”Fungal Balls” Complicating COVID-19. J Investig Med High Impact Case Rep . 2020;8:2324709620966475.
[4] Blandin S, David G. L’aspergillose en pratique pour le pneumologue. Rev Pneumol Clin . 2008;64(4):202-210.
[5] Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med . 2018;141:121-131.
[6] El-Baba F, Gao Y, Soubani AO. Pulmonary Aspergillosis : What the Generalist Needs to Know. Am J Med . 2020;133(6):668-674.
[7] Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M et al. Defining and managing COVID-19-associated pulmonary aspergillosis : the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis . 2021;21(6):e149-e162.
[8] Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Binder et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine . 1982;61:109-24.
[9] Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S et al. European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J . 2016;47(1):45-68.